Lorazepam as a sedative-amnesic in an intensive care unit

Area of Science:

• Critical Care Medicine
• Pharmacology
• Respiratory Therapy

Background:

• Intensive care units (ICUs) require effective sedation for critically ill patients, often utilizing opiate narcotics or diazepam.
• Alternative sedative agents are sought to improve patient outcomes and reduce side effects.
• Lorazepam, a benzodiazepine, has potential sedative properties for ICU settings.

Purpose of the Study:

• To evaluate the clinical usefulness of intravenous lorazepam as a sedative in critically ill patients.
• To compare lorazepam's efficacy and safety against opiate narcotics or diazepam.
• To assess lorazepam's impact on hemodynamic stability and patient recall.

Main Methods:

• A clinical study involving 25 critically ill patients in a respiratory and intensive care unit.
• Intravenous lorazepam (4 mg) administered every 4-6 hours for up to 25 days.
• Continuous monitoring of electrocardiogram (ECG), hemodynamic parameters, and biological markers.
• Cardiac output measurement after single doses of 4 mg or 8 mg lorazepam in a subset of patients.

Main Results:

• Lorazepam demonstrated usefulness as a sedative, with patients experiencing diminished recall.
• No significant side effects or local injection site reactions were reported.
• Hemodynamic stability was maintained, with no significant changes in cardiac output observed.

Conclusions:

• Intravenous lorazepam is a useful sedative agent for critically ill patients in intensive care settings.
• Lorazepam offers a favorable safety profile with minimal side effects and no adverse hemodynamic impact.
• Further research may explore optimal dosing and long-term efficacy in diverse ICU populations.